Andreoli, M. T. (2015) “Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration”, Digital Journal of Ophthalmology. Boston, Massachusetts, USA, 21(3), pp. 29–34. doi: 10.5693/djo.01.2015.04.002.